SEOUL, South Korea, Dec. 15, 2025 /PRNewswire/ -- ADEL, Inc., a biopharmaceutical company dedicated to developing therapies for neurodegenerative diseases such as Alzheimer's Disease, today announced ...

ADEL-Y01, a monoclonal antibody targeting tau protein, is in Phase I trials for Alzheimer's disease, developed by ADEL and licensed to Sanofi. The ADEL-Sanofi agreement is valued at over $1.04 billion ...

Dec 16 (Reuters) - South Korea-based ADEL said late on Monday that it has entered a $1.04 billion partnership with French drugmaker Sanofi (SASY.PA), opens new tab to develop and sell the biotech ...

Adel (ADEL), which is jointly developing an Alzheimer's disease drug candidate with Oscotec, said on the 16th that it signed a technology transfer agreement with French drugmaker Sanofi to transfer ...

Sanofi is back with its second pact of the day, this time announcing a licensing deal for a South Korean biotech’s antibody therapy designed to treat Alzheimer's disease. The French pharma is paying ...

Since Israel and Hamas went to war, reporters and editors at The New York Times have closely covered the conflict. Our coverage includes the Hamas-led attack on Israel, the plight of hostages, how the ...

Thank you for reporting this station. We will review the data in question. You are about to report this weather station for bad data. Please select the information that is incorrect.

Thank you for reporting this station. We will review the data in question. You are about to report this weather station for bad data. Please select the information that is incorrect.